Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

How to manage cyber risk as a strategic imperative
If a ransomware event shuts down a critical system, your board will focus on operations, revenue and recovery long before it discusses the technical
Soft markets, AI and next steps for London Market pricing
The twin impacts of softening markets and AI mean that London Market pricing teams will need to evolve their approach rapidly over the coming years.
Flood risk in changing climate: What risk managers must know
Flood risks are not restricted to those places labelled as flood zones. Neil Gunn and Hayley Fowler look at why flooding can occur well beyond mapped

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.